The global urinary tract cancer market size was worth around USD 2.74 billion in 2023 and is predicted to grow to around USD 12.28 billion by 2032 with a compound annual growth rate (CAGR) of roughly 18.24% between 2024 and 2032.

Cancer is an adverse disease caused due to abnormal cell growth with the potential to spread or invade all over the body. Urinary tract cancer is generally known as bladder cancer. Uncontrolled growth of cells in the urinary tract is said as bladder cancer. Bladder cancer is recognized as the most common symptom which is the presence of blood in the urine. Urine tract cancer is mainly observed among smokers, the generic population, workers in chemical industries and people with prolonged urine infections. The patient can survive in the bladder cancer if identified at early stages.

Request Free Sample

Growth of the global urinary tract cancer market is majorly driven by an increase in prevalence of bladder cancer; rise in funding from private & government organizations for development of research centers; rise in growth of geriatric population; and increase in R&D activities in the healthcare sector. Bladder cancer is the 10th most common cancer, across the globe. For instance, according to American Cancer Society, in 2021, it was reported that around 83,730 population are diagnosed with bladder cancer, in the U.S. Moreover, the University investment and philanthropic donations funded $1.18 million to the bladder cancer research centers, which was launched in the University of Birmingham, in the UK. In addition, rise in geriatric population who are more vulnerable to bladder cancer fuels the market growth during the forecast period.

The aging population are more prone to urinary tract cancer due to weakening of immune cells that fight against the cancer tissue in bladder. According to American society of clinical oncology (ASCO) organization, in January 2021, it was reported that around 90% of the people with bladder cancer are more than 55 year of age.  Furthermore, according to American cancer society, 2019, it was observed that smoking along with workplace exposure can act together to cause bladder cancer. For instance, in August 2021, Merck, one of the leading global biopharmaceutical company, announced the U.S. Food and Drug Administrative approval for Keytruda (pembrolizumab), which is used for the treatment of Urothelial Carcinoma. Thus, the increasing number of approval for treatment of urinary tract cancer, and surge in sedentary life style such as smoking and rise in exposure to chemical industry propel the growth of the market. Moreover, the presence of highly specialist urologist for the treatment of cancer, and increase in number of cancer research centers.

Request For Customization

However, risk associated with the use of drug prescribed for urinary tract cancer such as irritation in bladder, blood in urine, and infection is expected to restrict the market growth during the forecast period.

Urinary Tract Cancer Market Segmentation

The urinary tract cancer market is segmented on the basis of cancer type, treatment type, distribution channel, and region. By cancer type, the market is categorized into bladder cancer, urethral cancer, and ureteric and renal pelvic cancer. 

By treatment type, the market is divided into chemotherapy, and immunotherapy. By distribution channel, the market is fragmented into retail pharmacy, and online pharmacy.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Segment review

Depending on cancer type, the bladder cancer segment dominated the market in 2020, and is expected to continue this trend during the forecast period, owing to increase in healthcare expenditure, advancement in available therapies, and increase in prevalence of bladder cancer. However, the ureteric and renal pelvic cancer segment is expected to witness considerable market growth during the forecast period, owing to increase in prevalence of renal pelvic cancer, availability of novel drugs and rise in geriatric population.

KEY BENEFITS FOR STAKEHOLDERS

 

  • The study provides an in-depth analysis of the urinary tract cancer market, and the current trends and future estimations to elucidate imminent investment pockets.
  • It presents a quantitative analysis of the market from 2021 to 2030 to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the market based on procedures and services assists to understand the trends in the industry.
  • Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

 

Buy Now

Urinary Tract Cancer Market: Competitive Analysis

The global urinary tract cancer market is dominated by players like:

 

 

The report segments of the urinary tract cancer market into:

Urinary Tract Cancer Market: By Type Segment Analysis

 

  • Squamous Cell Carcinoma
  • Adenocarcinoma
  • Urothelial Carcinoma
  • Other

 

Urinary Tract Cancer Market: By Diagnostic Techniques Segment Analysis

 

  • Cystoscopy
  • Transurethral Resection of Tumor
  • Imaging tests
  • Urine analyses
  • Others

 

Urinary Tract Cancer Market: By Treatment Segment Analysis

 

 

Urinary Tract Cancer Market: By Regional Segment Analysis

 

  • North AmericaU.S.
  • EuropeUKFranceGermany
  • Asia PacificChinaJapanIndia
  • Latin AmericaBrazil
  • Middle East & Africa